We are live on ! Find out more
BLRX

BioLineRX
BLRX

Fund managers haven’t disclosed any holdings of BLRX yet.

BLRX Hedge Fund Activity: Q1 2026 in Review

13 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2026, worth a combined $45.2K — down 67% from $136K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BLRX and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.

The largest buyer was XTX Topco, opening a new position worth an estimated $30.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $104K sold.

  • 13 institutional investors held BioLineRX (BLRX) as of Q1 2026, down from 14 in Q4 2025.
  • Funds reported $45.2K of BioLineRX stock for Q1 2026, down 67% quarter-over-quarter.
  • 1 fund opened new BioLineRX positions in Q1 2026 and 2 closed out, a net change of -1 holder.
  • The largest BioLineRX buyer in Q1 2026 was XTX Topco, an estimated $30.7K added.
  • The largest BioLineRX seller in Q1 2026 was Citadel Advisors, an estimated $104K sold.

Based on aggregated 13F filings for Q1 2026.